Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.

Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM.

Cancer Res. 2014 Jun 15;74(12):3205-17. doi: 10.1158/0008-5472.CAN-13-3461. Epub 2014 Apr 15.

2.

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ.

Cancer Immunol Res. 2014 Nov;2(11):1044-50. doi: 10.1158/2326-6066.CIR-14-0074. Epub 2014 Sep 2.

3.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ.

J Clin Invest. 2013 Mar;123(3):1371-81. doi: 10.1172/JCI66236. Epub 2013 Feb 1. Erratum in: J Clin Invest. 2013 Jul 1;123(7):3182. J Clin Invest. 2016 Jan;126(1):402-3.

4.

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.

Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.

Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16.

5.

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.

Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A.

BMC Cancer. 2015 May 5;15:356. doi: 10.1186/s12885-015-1377-8.

6.

Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.

Cintolo JA, Datta J, Xu S, Gupta M, Somasundaram R, Czerniecki BJ.

Melanoma Res. 2016 Feb;26(1):1-11. doi: 10.1097/CMR.0000000000000203.

PMID:
26451873
7.

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S.

Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18.

8.

p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.

Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G.

Eur J Cancer. 2016 Mar;55:98-110. doi: 10.1016/j.ejca.2015.12.002. Epub 2016 Jan 17.

PMID:
26790143
9.

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC, Zheng B.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18226-31. doi: 10.1073/pnas.1317577110. Epub 2013 Oct 21.

10.

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

Shi H, Kong X, Ribas A, Lo RS.

Cancer Res. 2011 Aug 1;71(15):5067-74. doi: 10.1158/0008-5472.CAN-11-0140.

11.

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD.

Clin Cancer Res. 2011 Feb 15;17(4):721-30. doi: 10.1158/1078-0432.CCR-10-2225. Epub 2010 Nov 18.

12.

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S.

Oncologist. 2011;16(3):296-309. doi: 10.1634/theoncologist.2010-0317. Epub 2011 Feb 25.

13.

Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.

Lai F, Guo ST, Jin L, Jiang CC, Wang CY, Croft A, Chi MN, Tseng HY, Farrelly M, Atmadibrata B, Norman J, Liu T, Hersey P, Zhang XD.

Cell Death Dis. 2013 Jun 6;4:e655. doi: 10.1038/cddis.2013.192.

14.

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P.

Clin Cancer Res. 2013 Jan 15;19(2):393-403. doi: 10.1158/1078-0432.CCR-12-1626. Epub 2012 Nov 30.

15.

Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response.

Yang J, Hawkins OE, Barham W, Gilchuk P, Boothby M, Ayers GD, Joyce S, Karin M, Yull FE, Richmond A.

Cancer Res. 2014 Dec 15;74(24):7274-84. doi: 10.1158/0008-5472.CAN-14-1091. Epub 2014 Oct 21.

16.

Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.

Jenkins MH, Steinberg SM, Alexander MP, Fisher JL, Ernstoff MS, Turk MJ, Mullins DW, Brinckerhoff CE.

Pigment Cell Melanoma Res. 2014 May;27(3):495-501. doi: 10.1111/pcmr.12220. Epub 2014 Mar 6. No abstract available.

17.

Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.

Basile KJ, Le K, Hartsough EJ, Aplin AE.

Pigment Cell Melanoma Res. 2014 May;27(3):479-84. doi: 10.1111/pcmr.12218. Epub 2014 Feb 10.

18.

BRAF V600E is a determinant of sensitivity to proteasome inhibitors.

Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F.

Mol Cancer Ther. 2013 Dec;12(12):2950-61. doi: 10.1158/1535-7163.MCT-13-0243. Epub 2013 Oct 9.

19.

Cyp24a1 Attenuation Limits Progression of BrafV600E -Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAFV600E Inhibitor PLX4720.

Zou M, Baitei EY, BinEssa HA, Al-Mohanna FA, Parhar RS, St-Arnaud R, Kimura S, Pritchard C, Alzahrani AS, Assiri AM, Meyer BF, Shi Y.

Cancer Res. 2017 Apr 15;77(8):2161-2172. doi: 10.1158/0008-5472.CAN-16-2066. Epub 2017 Feb 27.

PMID:
28242615
20.

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.

Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.

Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.

Supplemental Content

Support Center